Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Wolfgang Ulrich Knauf, MD, Wolfgang Abenhardt, MD, Arnd Nusch, MD, Renate Grugel, Norbert Marschner, MD

Blood (2012) 120 (21): 4605.

https://doi.org/10.1182/blood.V120.21.4605.4605

Published: 2012

Journal Articles

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

Wolfgang Ulrich Knauf, MD, Wolfgang Abenhardt, MD, Arnd Nusch, MD, Renate Grugel, Norbert Marschner, MD

Blood (2012) 120 (21): 3666.

https://doi.org/10.1182/blood.V120.21.3666.3666

Published: 2012

Journal Articles

Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Marina Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Françoise Huguet, MD, Ilaria Del Guidice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo

Blood (2010) 116 (21): 2449.

https://doi.org/10.1182/blood.V116.21.2449.2449

Published: 2010

Journal Articles

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, MD, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Francoise Huguet, MD, Ilaria Del Giudice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo, MD

Blood (2009) 114 (22): 2367.

https://doi.org/10.1182/blood.V114.22.2367.2367

Published: 2009

Journal Articles

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Peter Dreger, Hartmut Döhner, Hildegard Greinix, MD, Fabienne McClanahan, MD, Manfred Hensel, Bernd Hertenstein, Ulrich Dührsen, MD, PhD, Markus Hentrich, Lorenz Trümper, Ruth Sonnen, Bertold Emmerich, Wolfgang Ulrich Knauf, Georg Hopfinger, MD, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, Stephan Stilgenbauer, MD

Blood (2009) 114 (22): 879.

https://doi.org/10.1182/blood.V114.22.879.879

Published: 2009

Journal Articles

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.

Wolfgang Ulrich Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna Liberati, Javier Loscertales, Roul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, Liana Gercheva, Stefan Goranov, MD, Martin Becker, Klaus Hoeffken, Francoise Huguet, Robert Foa, MD, Karlheinz Merkle, Marco Montillo

Blood (2008) 112 (11): 2091.

https://doi.org/10.1182/blood.V112.11.2091.2091

Published: 2008

Journal Articles

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Wolfgang Ulrich Knauf, MD, Toshko Lissichkov, M.D., Ali Aldaoud, M.D., Raoul Herbrecht, M.D., Anna Marina Liberati, M.D., Javier Loscertales, M.D., Gunnar Juliusson, M.D., Christian Dittrich, M.D., Karlheinz Merkle, M.D.

Blood (2007) 110 (11): 2043.

https://doi.org/10.1182/blood.V110.11.2043.2043

Published: 2007

Journal Articles

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Wolfgang Ulrich Knauf, MD, Burkhard Otremba, MD, Friedrich Overkamp, MD, Susanne Bammer, PhD, Ralf Angermund, MD

Blood (2006) 108 (11): 5109.

https://doi.org/10.1182/blood.V108.11.5109.5109

Published: 2006

Journal Articles

Bendamustine Versus Chlorambucil in Treatment-Naive B-CLL Patients.

Wolfgang Ulrich Knauf, M.D., Toshko Lissitchkov, M.D., Raoul Herbrecht, M.D., Javier Loscertales, M.D., Ali Aldaoud, M.D., Karlheinz Merkle, M.D.

Blood (2004) 104 (11): 4817.

https://doi.org/10.1182/blood.V104.11.4817.4817

Published: 2004

Journal Articles

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Holger Schulz, Saskia Karina Klein, Ute Rehwald, Marcel Reiser, Axel Hinke, Wolfgang-Ulrich Knauf, Walter-Erich Aulitzky, Manfred Hensel, Michael Herold, Dieter Huhn, Michael Hallek, Volker Diehl, Andreas Engert

Blood (2002) 100 (9): 3115–3120.

https://doi.org/10.1182/blood-2002-03-0972

Published: 2002

NARROW

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Bendamustine Versus Chlorambucil in Treatment-Naive B-CLL Patients.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only